About US
Contact us
-
Mylan fails in hostile quest to buy PerrigoPharma's longest-running takeover battle of the year has come to an end--and not in pursuer Mylan's ($MYL) favor. The company has failed to garner the support necessary for a takeover of Perrigo ($PR2015/11/16
-
AstraZeneca hikes full-year forecast as Nexium holds its own, Brilinta deliversAstraZeneca ($AZN) has so far weathered theNexiumpatent cliff well enough to actually raise its full-year sales forecast for 2015. ItsBrilintagrowth strategy appears to be paying off. But the U.K.-bas2015/11/6
-
U.K. cancer fund strikes discount deal with Roche to keep Kadcyla coveredLast month, the U.K.'s special Cancer Drugs Fund gave the boot to a slate of therapies, including Roche's ($RHHBY) treatmentKadcyla--a decision the Swiss drugmaker's CEO called "stupid" and "completel2015/11/6
-
Everybody's talking about the Pfizer-Allergan courtship. Here's the juiciest chat we overheardThe deal of the year could be arranged by Thanksgiving, or so goes the story. Despite opposition from politicians, despite the tricky nature of pulling off a tax inversion that size, Pfizer ($PFE) and2015/11/3
-
FDA cites Pfizer for shortfalls at Chinese manufacturing plantTheFDAand European regulators, which have long had concerns about the quality of drugs being manufactured by Chinese companies, are now finding issues at some Chinese plants owned by Big Pharma. The F2015/11/3
-
How much can J&J make of Yondelis' long-sought FDA approval?After years of setbacks, Johnson & Johnson's ($JNJ) Yondelis finally has its shot at some U.S. sales. The drug won its sought-after FDA approval Friday--not in ovarian cancer as previously hoped,2015/10/27
-
Merck discounts Remicade in U.K. as it tries to fend off biosimilarsMerck & Co. has seen its sales of the blockbuster Remicade beaten up in Europe as biosimilars makers have been much more aggressive about discounting their copies of the arthritis med than anyone2015/10/27
-
Can GSK's volume strategy offset generic attack on blockbuster Avodart?GlaxoSmithKline ($GSK) has one less tool for propping up its top line. The company's prostate drugAvodartnow faces a generic version from Teva Pharmaceutical Industries ($TEVA), with more copycats exp2015/10/13
-
BMS' Opdivo gets a jump on Keytruda with another early FDA approvalReady for the lung cancer showdown between Merck & Co.'s ($MRK)Keytrudaand Bristol-Myers Squibb's ($BMY)Opdivo? It's here, and way ahead of schedule. Merck scoredFDAapproval for Keytruda in lung2015/10/13
-
Takeda keeps Actos settlement ball rolling with new resolutionsTakedais settling up with two more plaintiffs over allegedly hiding cancer risks linked to its diabetes drugActosjust weeks after it rolled up thousands of other outstanding cases as part of a multibi2015/10/12